Clinical Trial Update: Pharmacodynamics of Intermittent IL-2 Infusions in HIV Seropositive Patients [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the pharmacodynamics of intermittent interleukin-2 infusions in HIV-infected individuals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Proleukin (interleukin-2) (aldesleukin)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infection | Phase 2 | Status: COMPLETED